The insider sales are immaterial in dollar terms, no bearish signal. Monitor for upcoming pipeline or regulatory catalysts, as QURE is a gene therapy biotech with high stock volatility. The recent historical reports show large price swings following prior filings, but this cluster alone does not warrant a directional trade.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jun 18 $46.29entry
- T+1 · 5mo ago −4.10%α −3.79% · $44.39
- T+5 · 5mo ago +6.07%α +7.74% · $49.10
- T+20 · 4mo ago −14.97%α −15.50% · $39.36
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nine insiders at uniQure N.V. (QURE) sold a total of $1.2M in shares over a 7-day window, representing approximately 0.07% of the company's $1.7B market cap. The sales are small relative to company size and include both directors and two C-suite officers (Chief Legal Officer and Chief Customer & Strategy Officer). Despite the cluster of sellers, the dollar amounts are trivial and likely routine, not signaling a material bearish view.
Key Financial Metrics
Key Facts
- Total insider sales: $1.2M across 9 insiders in a 7-day window
- Sales represent only ~0.07% of QURE's $1.7B market cap
- Participants include Chief Legal Officer ($145K) and Chief Customer & Strategy Officer ($431K), plus 7 directors
- One director (Balachandran Madhavan) exercised derivatives alongside an open-market sale
Financial Impact
Insider sales total $1.2M, a trivial amount relative to the $1.7B market cap
Risk Factors
- Low insider selling volume provides no negative signal
- No material financial or operational news accompanies this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1781730167729 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers